Dr Reddys Laboratories
Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leader in the development and manufacturing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. With a strong presence in markets across North America, Europe, and Asia, Dr. Reddy's is committed to providing affordable healthcare solutions. The company’s core offerings include generic formulations, biosimilars, and over-the-counter products, distinguished by their quality and innovation. Dr. Reddy's has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position. Recognised for its commitment to sustainability and patient-centric approach, Dr. Reddy's Laboratories continues to make strides in enhancing global health outcomes.
DitchCarbon Score
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr Reddys Laboratories's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dr Reddys Laboratories's reported carbon emissions
In 2024, Dr Reddy's Laboratories, headquartered in India, reported total greenhouse gas emissions of approximately 189,530,000 kg CO2e for Scope 1, 114,655,000 kg CO2e for Scope 2, and 866,992,000 kg CO2e for Scope 3. This marked a decrease from 2023, where emissions were 214,257,000 kg CO2e (Scope 1), 137,627,000 kg CO2e (Scope 2), and 921,055,000 kg CO2e (Scope 3). Dr Reddy's Laboratories has set ambitious climate commitments, aiming for a 100% renewable power supply by 2030. Additionally, the company has committed to reducing its Scope 1 and 2 greenhouse gas emissions by 50.2% per million USD revenue by FY2031, relative to a FY2021 baseline, which translates to a 25% absolute reduction. For Scope 3 emissions, the target is a 12.3% reduction within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit temperature rise to well below 2°C. The company’s emissions data is self-reported and does not cascade from any parent organization. Dr Reddy's Laboratories is actively working towards these goals, reflecting its commitment to sustainability and climate action in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 177,841,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 254,563,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dr Reddys Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
